Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

Summary

A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral dose of GBT440 administered in subjects with mild, moderate, or severe renal impairment disease and healthy subjects with normal renal function.

Timeline

Start

2016-11

Primary completion

2017-05-25

Completion

2017-07-06

Drugs

Indications